Navigation Links
NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
Date:9/9/2013

CLEVELAND, Sept. 9, 2013 /PRNewswire-USNewswire/ -- NovelMed Therapeutics (www.novelmed.com) announced the receipt of a combined $1.43 million SBIR Grant from the NIH. The first installment of the award (for $542,572) will be used to evaluate NovelMed's lead candidate's therapeutic superiority for treating Paroxysmal Nocturnal Hemoglobinuria (PNH).  Subsequent funding, to be released on demonstration of superiority, will be used for later stage development.  The NIH award represents a major step toward commercialization of the Company's orphan disease therapy platform.

(Logo: http://photos.prnewswire.com/prnh/20130909/DC73243LOGO )

The grant follows strong evidence from recent studies that its lead candidate will block intra- and extra-vascular hemolysis, both of which must be controlled in order to gain advantages over eculizumab. These studies indicate that NovelMed's lead candidate could have a superior efficacy, safety and dosage profile relative to eculizumab.  The project will compare the two therapies under various experimental conditions.

"As a small business we applaud the support of the NIH in transitioning promising technologies from the laboratory to the clinic. We are honored that the scientific peer-review process at the NIH has repeatedly deemed our developmental concepts worthy of continued support as we advance the development of life-changing products," stated Rekha Bansal, Ph.D., Founder and Chief Executive Officer of NovelMed.

About PNH

PNH is a rare and life-threatening blood disorder where the immune system attacks red blood cells resulting in significant disease outcomes including red blood cell destruction and long-term anemia. Current treatment options are limited and only control cell destruction via the intravascular pathway. Despite staggering success of the current complement inhibitor being marketed, some patients continue to remain anemic due to the second newly-discovered pathway for red blood cell destruction also known as "extravascular hemolysis". NovelMed's leading drug candidate prevents red blood cell destruction via both pathways and therefore is expected to provide significant benefit in the total control of anemia.

About NovelMed

NovelMed Therapeutics, Inc., a privately-held biotech located in Cleveland, Ohio, is developing transformative treatments for orphan and non-orphan disease conditions.  The company has developed a portfolio of antibodies targeted for the treatments of complement-mediated inflammatory and hemolytic disorders including paroxysmal nocturnal Hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (Dry & Wet AMD), arthritis (RA & OA), and cardiovascular diseases.  NovelMed's drug candidates are differentiated by their unique mechanism(s) of action that are expected to deliver therapies with superior efficacy, safety and dosage profiles. The company is currently looking for strategic partners for clinical trials and commercialization of its therapeutic drugs.

Similar drug discovery is being pursued by a few companies including Roche/Genentech and Novartis, which are both pursuing AMD therapies, and Alexion which is currently marketing Soliris (eculizumab), an FDA approved antibody-based therapy.

Disclaimer

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Research reported in this press release was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number R44HL115909.  


'/>"/>
SOURCE NovelMed
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
2. QBC Diagnostics Awarded GSA Contract
3. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
4. Northwest Bio Awarded $5.5 Million German Government Grant
5. Nonin Medical Awarded Novation Contract for Clinically Proven Pulse Oximeters
6. Elsevier / Gold Standards Kay Morgan Awarded NCPCP Highest Honor
7. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
8. New Chronic Wound Therapy Awarded at Texas Largest Life Science Event
9. SurgiCount Medical Awarded Contract From HealthTrust Purchasing Group for the Safety-Sponge® System
10. Sorrento Therapeutics Awarded Third Phase I STTR Grant
11. Texas A&M System Awarded National Center for Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , February 12, 2016 /PRNewswire/ ... nicht anders vermerkt)   http://www.sedar.com ... http://www.telestatherapeutics.com abrufbar.    --> ... des Unternehmens http://www.telestatherapeutics.com abrufbar.    ... (TSX:TST; PNK:BNHLF) veröffentlichte heute seinen Konzernabschluss des ...
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... 2016 On Thursday, Feb. 11, 2016, surgeons ... David,s North Austin Medical Center successfully completed the first ... ® Surgical System with Trumpf Medical,s advanced operating ... Lakshman , M.D., colorectal surgeon at the Texas Institute ... Table Motion technology, which seamlessly combines the da Vinci ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... ... CDRH Enforcement Trends: , Back to the Future , Feb. 25, 2016 — 11:00 a.m. ... “Those who don’t learn from history are doomed to repeat it.” , An analysis of ... year. But that takes time. , Take a close look at the warning letters ...
(Date:2/12/2016)... ... , ... As a former television executive, owner Tal Rabinowitz knows how stressful ... decompress, Rabinowitz found herself drawn to a casual meditation class while working at NBC ... implementing a 20-minute-per-day meditation practice with her team. After her tenure at NBC, she ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare Center for ... General Hospital on April 5-7. The series is a multi-day, multi-workshop event designed ... workshops cover a broad range of topics, including coaching skills, the scientific method ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and CEO ... Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern ... Nevada Healthcare System. This will be the first Fisher House in Nevada, and ...
(Date:2/12/2016)... ... February 12, 2016 , ... Vail knee specialist Robert LaPrade, MD, ... in 2016 . The list consists of physicians establishing, leading and partnering with ambulatory ... , An Ambulatory Surgery Center, also known as an ASC, is a modern ...
Breaking Medicine News(10 mins):